Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Biotech IPOs see gradual resurgence in Q3 2023, investor caution persists

EditorRachael Rajan
Published 2023-10-03, 10:50 a/m
© Reuters.
APOG
-
LXRX
-
ALVIO
-
KAI
-
ABVX
-

Initial public offerings (IPOs) in the biotechnology sector are showing signs of revival, with eight companies raising $1.1 billion from July through September 2023, according to data compiled by BioPharma Dive. This compares to four biotech firms that raised approximately $580 million in the second quarter.

However, the market's response to these IPOs has been mixed. Only two of the eight biotechs that debuted in the third quarter, RayzeBio and Apogee (NASDAQ:APOG) Therapeutics, were trading above their debut share price as of Monday. Notably, Neumora Therapeutics, backed by Arch Venture Partners and Amgen (NASDAQ:AMGN), saw its share price drop by a third since its IPO on September 14.

In contrast to previous years, newly public drugmakers are not enjoying rising valuations as many companies that went public in 2020 and 2021 did. This reflects investor concerns about lack of data and a preference for safer bets amid economic uncertainty. Mike Perrone, a managing director at Baird, emphasized that investors now want to see strong proof of concept and a high-quality team before backing a company in the public markets.

A report from accounting and consulting firm EY noted a decline in "unicorn" IPOs - offerings involving companies valued at over $1 billion privately. As per EY's findings, no health and life sciences companies to IPO through September 18 met this criteria in 2023, compared to four during the first three quarters of 2022.

Despite these challenges, there are signs that the fourth quarter could be busier. Three biotech firms - Lexeo Therapeutics, Abivax, and Kairos Pharma - filed plans to go public on Friday. All three have at least one drug in early-stage human testing, aligning with analysts' predictions about which companies would be in the strongest position to launch an IPO.

Jack Bannister, a senior managing director at Leerink Partners, stated that the appetite to invest in the sector has not diminished. He, along with Perrone, noted that many other companies are quietly preparing for IPOs, such as by making confidential filings.

However, the perception of safety around experimental drugs has shifted. Bannister highlighted that having a drug in a Phase 3 trial is no longer considered as safe as it once was. This change in sentiment is reflected in several later-stage assets failing just months after their IPOs, despite having a deep pool of clinical data.

One notable example is Acelyrin. The California-based biotech encountered a significant obstacle in late-stage clinical testing of its anti-inflammatory drug izokibep in September, causing its share prices to plummet just four months after a successful IPO.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.